Identifying candidates with promising ADME and pharmacokinetics properties during the discovery phase of drug development lays the groundwork for future clinical trials and regulatory approval. However, translating a long-term study into a successful outcome requires reliable, qualified measurements at a clinical scale.
Q2 Solutions’ global bioanalytical services network brings substantial expertise in biomarker assays and cell-based bioanalytical assays that target multi-domain proteins, antibodies, oligonucleotides, antibody-drug conjugates, and peptides.
Specific strengths include:
Supporting data from high-volume, regulated clinical studies
Solutions for your large molecule bioanalysis and the successful outcome you seek
If you’re looking for solutions to analytical challenges, you’ve come to the right place. Our highly trained scientists partner with you to provide a well-planned strategy, no matter where you are in...
Q2 Solutions is a leading drug discovery and development laboratory services organization with over 30 years of experience specializing in GLP-compliant bioanalytical testing. Our updated and...
The analysis and distribution of pharmaceuticals in tissue is increasingly important in understanding the full action of drugs in vivo. Across molecular types from very small molecules to larger...